SUMMARY
Background: Cerebral vein thrombosis (CVT) has been considered until a few years ago an uncommon disease with significant long-term morbidity and a high mortality rate. New non-invasive diagnostic techniques have increased the frequency with which this disease is diagnosed; despite this, there continues to be little data on its natural history.
Objectives: To evaluate the mortality rate, the rate of disability at long-term follow-up and the incidence of recurrences after a first episode of CVT; to determine clinical and radiological predictors of death and dependence; and to identify possible risk factors for recurrence.
Data source: MEDLINE and EMBASE databases, reference lists of selected articles and authors' libraries Results and conclusion: Nineteen studies were identified. Mortality rate during perihospitalization period is 5.6 % (range 0 to 15.2%), and 9.4 % (range 0 to 39%) at the end of follow-up period. Eighty-eight percent of surviving patients recover completely or have only a mild functional or cognitive deficit. Two third of patients with CVT recanalized within the first few months after presentation and 2.8 % (range 0 to 11.7%) had objectively confirmed recurrence. We conclude that patients with CVT have a low risk of death and most patients have a good long-term prognosis.
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INTRODUCTION
Cerebral vein thrombosis (CVT) is a rather uncommon disease. However, the recent introduction of non-invasive and highly sensitive diagnostic techniques such as magnetic resonance imaging (MRI), magnetic resonance angiography (MRA) and computed tomography angiography (CTA) has modified our knowledge of the spectrum of illness associated with CVT. The ability to accurately detect less clinically severe cases of CVT has modified the "natural history" of this disorder. Thus, in contemporary series, the reported mortality rate ranges between 8 and 14 % [1] [2] [3] [4] and it is in contrast with prior studies within which cause-specific mortality was as high as 30 to 50 % 5 . Although some patients with CVT present with catastrophic complications, such as a stroke syndrome with focal neurological signs or coma, many present with mild or non-specific symptoms such as isolated intracranial hypertension presenting with headache and papilledema 1-4, 6, 7 . However, conversely to arterial stroke, scarce information exists on natural history and long-term prognosis of CVT. Existing studies are often limited by small numbers, their retrospective nature and short follow-up. In an effort to better understand the natural history of CVT, we performed a systematic research on the existing literature. Our aims were to evaluate the acute and long-term mortality rate of patients with CVT; to evaluate clinical outcomes and the rate of disability over long-term follow-up; to determine clinical and radiological predictors of death and dependence; to estimate the cumulative incidence of recurrent CVT after a first episode of CVT and to identify possible risk factors for recurrent CVT.
METHODS
A computer-assisted search was performed to identify all published studies that evaluated the natural history of CVT. Studies were identified using MEDLINE (from 1966 to Studies were included when they fulfilled the following a priori defined inclusion criteria:
(1) they contained original data; (2) diagnosis of CVT was objectively confirmed (with digital substraction or conventional angiography, magnetic resonance imaging or magnetic resonance angiography, computed tomography venography, at surgery or with autopsy); (3) patients were 18 years or older; (4) they included at least ten patients; (5) they had a follow-up of at least three months; (6) they provide information on one or more of the following data: mortality and disability rate, clinical or radiological predictors of poor outcome, recanalization, recurrence of CVT.
Additional papers meeting these inclusion criteria were selected for review from the authors' libraries, and from review of the reference lists of those articles selected for detailed review.
We excluded all studies in which the diagnosis of CVT was exclusively clinical without objective imaging, and all the studies in which residual disability was not measured clearly or with a commonly accepted score (i.e. modified Rankin Score, Glasgow Outcome Scale). When multiple papers for a single study had been published, we used the latest publication and we supplemented it, if necessary, with data from the earlier publications.
For each study selected two reviewers (MG, FD) independently and in duplicate extracted data on study characteristics and the following outcomes: mortality, residual disability, recanalization, recurrence and potential radiological and clinical predictors of poor outcome. Acute mortality was defined as occurred in the first 30 days from diagnosis.
Disagreement was resolved by consensus or by opinion of a third reviewer (WA).
Patients with a modified Rankin Score (mRS) ranging between 0 and 2 or with a Glasgow Outcome Scale (GOS) ranging between 1 and 2 were considered with a favorable outcome, whereas patients with a mRS between 3 and 5 or survived patients with a GOS between 3 and 5 were considered to have a poor outcome.
Because the use of quality scoring systems in observational studies is controversial 8 , we assessed study quality considering 2 characteristics. First, we considered the study design:
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From prospective cohort studies were judged to be of higher quality compared to retrospective cohort studies. Second, we considered the enrollment: studies in which the enrollment of patients was consecutive were considered to be of higher quality compared to studies in which the enrollment was not consecutive. A formal combined meta-analysis of these studies was not appropriate due to the heterogeneity of methodology and outcome assessments among the trials, and therefore, a narrative synthesis of collected data was undertaken. Data are presented as mean, percentage and range of variation.
RESULTS

STUDY CHARACTERISTICS
Using our search strategy, we identified 812 studies. Twenty-two studies met inclusion criteria 1, 4, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . Three studies were extracted from two different publications; therefore, 19 studies were included in our systematic review 4, 9, [11] [12] [13] [14] [15] [16] [17] [18] [20] [21] [22] [23] [24] [25] [26] [27] [28] and supplemented with data of other 3 publications 1, 10, 19 . The main characteristics of the studies included in our systematic review are summarized in evaluated patients died within the first month (mean 5.6 %; range 0 to 15.2%). However, the mortality rate varied highly between the studies and was 0 in 5 studies. Thirty-two of 45 evaluated patients died as a consequence of cerebral vein thrombosis (most of them for cerebral herniation), whereas most of 13 died as a consequence of an underlying disease.
The overall mortality rate at the end of follow-up was 9.4 % (122 deaths in 1303 total patients). However, it was highly variable between the studies (range 0 to 39%).
Noteworthy, most of the deaths occurred during follow-up were related to an underlying condition such as cancer (24 of 38 evaluated deaths during follow-up) and they were not direct consequence of cerebral vein thrombosis.
DISABILITY
Outcome information was available for 7 studies at 3-6 months of follow-up 
RECANALIZATION
Five studies investigated the recanalization of cerebral venous thrombosis 10-12, 14, 17 (Table   3 ). Unfortunately, all these studies presenting data on recanalization have a relatively small sample size (ranging from 16 to 40 patients) and in total enrolled 154 patients. Four of these defined recanalization as complete (blood flow without any interruption), partial (small interruption of continuous blood flow and/or narrowing of the venous lumen), or absent (interrupted blood flow), and the other did not distinguish between partial and complete recanalization 14 . Recanalization was evaluated at 3-6 months in 4 studies [10] [11] [12] 14 , at 1 year in 3 studies 10, 12, 17 and at either or both time points in two studies 10, 12 . If the rates of recanalization presented in these studies are combined numerically, there was no difference in the rate of recanalization at three months and at one year of follow-up (59 of 70 (84%) at 3 months and 60 of 70 (85%) at 1 year). These results suggest that recanalization occurs only within the first months following CVT and not thereafter, irrespective of anticoagulation. No correlation between recanalization and clinical outcome was found in the two studies which examined this relationship 10, 17 .
RECURRENCE
The overall recurrence rate was presented in 13 studies; in these studies 2.8% (29 new CVT in 1048 patients evaluated; range 0 to 11.7 ) patients recurred (Table 5 ). There was only 1 recurrence in 103 pregnancies (0.97%; range 0 to 2.9%), however spontaneous abortion was a frequent complication in these patients.
PREDICTORS OF OUTCOME
Ten studies evaluated the predictors of poor or of good outcome 4, 9, 16, 18, 21, 23, 25-28 ( Table   4) . Using multivariate analysis, Ferro and colleagues 27 found that age of more than 37 years, male sex, coma, seizure, mental status disorder, deep CVT , right intracranial hemorrhage, posterior fossa lesion, worsening of previous focal or de novo focal deficits, cerebral nervous system infection and cancer were predictors of death or dependence.
Cancer, coma and intracranial hemorrhage were confirmed as predictors of poor outcome in other studies 4, 16, 21, 23, 26 . On the other hand, isolated intracranial hypertension at the time of diagnosis was found to be a predictor of good outcome in three studies 21, 25, 27 .
Noteworthy, Appenzeller et al. 28 found that presence of parenchymal involvement (hemorrhagic or ischemic) on CT or MRI was associated with an increased risk of developing neurological sequelae.
DISCUSSION
Our study confirmed that most patients with cerebral vein thrombosis have a more benign prognosis than previously suspected; 5.6 % of patients died during the acute phase and 9.4% of patients had died at the end of follow-up period. Conversely to acute phase, where most patients died due to cerebral herniation, during the follow-up period most patients had died due to underlying conditions such as cancer rather than as a result of direct consequences of their CVT. Most surviving patients recovered completely or had only mild functional or cognitive deficit; less then 1 in five surviving patient was dependent or had a permanent disability at the end of follow-up period. Patient characteristics likely to be associated with an adverse outcome include: age > 37 years old, presence of focal deficits at presentation, altered consciousness including coma at presentation, intracranial
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From hemorrhage, involvement of cortical veins and underlying cancer. More than two third of patients with CVT had partial or complete recanalization within the first few months after presentation; there was no evidence that recanalization occurred between 3 and 6 months after presentation. However, the potential benefit of a complete recanalization on the short or long-term outcome remains unknown. Recurrences of CVT after a first episode are uncommon occurring in 2.8% of patients. Young women, who developed CVT during pregnancy or puerperium, have a low risk of recurrence during subsequent pregnancies.
Our results confirm that CVT is a more benign disease than it was previously considered. This is likely due to several facts. First, more sensitive diagnostic techniques have undoubtedly led to the detection of smaller thrombi, which likely have better prognosis. Second, older series had patients with infection associated CVT; such events are very rare since the advent of antibiotics. Third, widespread treatment of CVT with anticoagulation has probably changed the natural history of this disease.
Our observations confirm that the natural history of CVT is different from that of arterial stroke. About 10% of stroke patients die during hospitalization 29 , approximately 20% die within one year after discharge 30 and about 35% of the hospitalized stroke survivors with motor deficits of the legs do not show any degree of motor recovery 31 . Only one of four stroke patients presents a complete neurological recovery during follow-up 32 .
Furthermore, the incidence of recurrent events is dramatically lower following CVT as compared to arterial cerebrovascular diseases and to venous thrombosis occurring in other sites. Indeed, about 4% of stroke patients experience a recurrence every year with a cumulative risk of recurrence at 10 years of 43 % 33 .
Our systematic review has limitations. First, although the number of patients lost at follow-up was generally low, we cannot exclude case-ascertainment bias in the underlying studies. The risk of this bias is increased by the fact that our analysis was limited to observational studies, some of which were retrospective. Second, mortality, residual disability and rate of recurrence varied widely between the studies suggesting some differences in populations examined. Third, although we obtained data on anticoagulant
almost all studies, it was not possible to know, in many cases, whether the patients who suffered a recurrence were receiving anticoagulants and if they were treated adequately at the time of recurrence. Finally, although we collected data from 19 studies and from more than 1400 patients, the total number of deaths and recurrences remained low not allowing definitive conclusions on these particular topics. However, the results of our systematic review are relevant because they add important knowledge on the natural history of cerebral vein thrombosis. Prior to this systematic review information on the natural history of the disease was rather inconclusive. Indeed, to date, only three studies that have included more than 100 patients have been published.
Other important aspects of CVT, such as risk factors and optimal treatment have not been addressed in our systematic review. The first issue was recently covered by our group in a meta-analysis, which showed that oral contraceptives-users, and patients with factor V Leiden, the prothrombin G20120A mutation and hyperhomocysteinemia are at significantly increased risk of CVT 34 . There are few good quality clinical trials published on the treatment of cerebral vein thrombosis 35, 36 limiting the quality of a systematic review of treatment for this disorder.
In conclusion, we found that about 85% of patients with CVT survive and that the majority of survivors have an excellent long-term outcome. Altered level of consciousness at presentation, intracranial hemorrhage and an underlying cancer are important adverse prognostic factors. Relapses are rare, but other thromboembolic events are not infrequent in these patients.
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